CD8A and neoplasm: Tumors from mice treated with FAK inhibition, gemcitabine and anti-PD1 therapy also had a significantly increased number of tumor-infiltrating CD8+ T-cells compared to mice treated with gemcitabine and anti-PD1 therapy without FAK inhibition [67].